Actually, targeting GFPT2 by azaserine and targeting PGM3 by FR054 can specifically inhibit KRAS/LKB1 combined mutant lung adenocarcinoma cells, respectively (Kim et al., 2020; Lee et al., 2022). This evidence concerns the gene STK11 and lung adenocarcinoma.